BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 15012984)

  • 1. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
    Pastorekova S; Casini A; Scozzafava A; Vullo D; Pastorek J; Supuran CT
    Bioorg Med Chem Lett; 2004 Feb; 14(4):869-73. PubMed ID: 15012984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
    Vullo D; Franchi M; Gallori E; Pastorek J; Scozzafava A; Pastorekova S; Supuran CT
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1005-9. PubMed ID: 12643899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
    Puccetti L; Fasolis G; Vullo D; Chohan ZH; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3096-101. PubMed ID: 15908204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
    Puccetti L; Fasolis G; Cecchi A; Winum JY; Gamberi A; Montero JL; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 May; 15(9):2359-64. PubMed ID: 15837325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
    Casey JR; Morgan PE; Vullo D; Scozzafava A; Mastrolorenzo A; Supuran CT
    J Med Chem; 2004 Apr; 47(9):2337-47. PubMed ID: 15084132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
    Garaj V; Puccetti L; Fasolis G; Winum JY; Montero JL; Scozzafava A; Vullo D; Innocenti A; Supuran CT
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3102-8. PubMed ID: 15905091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
    Garaj V; Puccetti L; Fasolis G; Winum JY; Montero JL; Scozzafava A; Vullo D; Innocenti A; Supuran CT
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5427-33. PubMed ID: 15454239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbonic anhydrase inhibitors: transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters.
    Vullo D; Steffansen B; Brodin B; Supuran CT; Scozzafava A; Nielsen CU
    Bioorg Med Chem; 2006 Apr; 14(7):2418-27. PubMed ID: 16321542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides.
    Franchi M; Vullo D; Gallori E; Pastorek J; Russo A; Scozzafava A; Pastorekova S; Supuran CT
    J Enzyme Inhib Med Chem; 2003 Aug; 18(4):333-8. PubMed ID: 14567548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII.
    Akocak S; Güzel-Akdemir Ö; Kishore Kumar Sanku R; Russom SS; Iorga BI; Supuran CT; Ilies MA
    Bioorg Chem; 2020 Oct; 103():104204. PubMed ID: 32891000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors.
    Winum JY; Cecchi A; Montero JL; Innocenti A; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3302-6. PubMed ID: 15908201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides.
    Cecchi A; Taylor SD; Liu Y; Hill B; Vullo D; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5192-6. PubMed ID: 16203142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.
    Almajan GL; Innocenti A; Puccetti L; Manole G; Barbuceanu S; Saramet I; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 May; 15(9):2347-52. PubMed ID: 15837323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
    Ozensoy O; Puccetti L; Fasolis G; Arslan O; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4862-6. PubMed ID: 16168653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
    Cecchi A; Ciani L; Winum JY; Montero JL; Scozzafava A; Ristori S; Supuran CT
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3475-80. PubMed ID: 18513964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbonic anhydrase inhibitors: design of membrane-impermeant copper(II) complexes of DTPA-, DOTA-, and TETA-tailed sulfonamides targeting the tumor-associated transmembrane isoform IX.
    Rami M; Cecchi A; Montero JL; Innocenti A; Vullo D; Scozzafava A; Winum JY; Supuran CT
    ChemMedChem; 2008 Nov; 3(11):1780-8. PubMed ID: 18956406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
    Güzel O; Maresca A; Scozzafava A; Salman A; Balaban AT; Supuran CT
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2931-4. PubMed ID: 19410461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
    Lehtonen JM; Parkkila S; Vullo D; Casini A; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3757-62. PubMed ID: 15203157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow synthesis and biological activity of aryl sulfonamides as selective carbonic anhydrase IX and XII inhibitors.
    Rosatelli E; Carotti A; Ceruso M; Supuran CT; Gioiello A
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3422-5. PubMed ID: 24948563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
    Brzozowski Z; Sławiński J; Innocenti A; Supuran CT
    Eur J Med Chem; 2010 Sep; 45(9):3656-61. PubMed ID: 20554082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.